{"nctId":"NCT00960076","briefTitle":"An 18 Week Efficacy and Safety Study of Saxagliptin and Metformin XR Combination in Subjects With Type 2 Diabetes","startDateStruct":{"date":"2009-08"},"conditions":["Type 2 Diabetes"],"count":282,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Drug: Saxagliptin","Drug: Metformin XR"]},{"label":"2","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Metformin XR"]}],"interventions":[{"name":"Saxagliptin","otherNames":["Onglyza"]},{"name":"Metformin XR","otherNames":[]},{"name":"Metformin XR","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Type 2 diabetics taking metformin IR or XR greater than or equal to 850mg and less than or equal to 1500mg only for at least 8 weeks prior to screening\n* A1c: 7.5-11% (at screening)\n* BMI less than or equal to 45 kg/m2\n\nExclusion Criteria:\n\n* Significant cardiovascular history\n* Active liver disease, renal impairment","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"78 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in HbA1c Level From Baseline to Week 18 (LOCF)","description":"Adjusted mean change from baseline in HbA1c achieved with saxagliptin added on to metformin versus metformin at Week 18 (Randomized Analysis Set). HbA1c is a continuous measure, the change from baseline for each participant is calculated as the Week 18 value minus the baseline value.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.41","spread":"0.076"},{"groupId":"OG001","value":"8.28","spread":"0.077"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.53","spread":"0.093"},{"groupId":"OG001","value":"7.93","spread":"0.111"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.88","spread":"0.077"},{"groupId":"OG001","value":"-0.35","spread":"0.076"}]}]}]},{"type":"SECONDARY","title":"Change in 2-hour PPG Following Mixed Meal Tolerance Test (MMTT) From Baseline to Week 18 (LOCF)","description":"Adjusted mean change from baseline in 2-hour PPG (following MMTT) achieved with saxagliptin added on to metformin versus metformin at Week 18 (Randomized Analysis Set). PPG is a continuous measure, the change from baseline for each participant is calculated as the Week 18 value minus the baseline value.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"227.36","spread":"6.022"},{"groupId":"OG001","value":"223.68","spread":"5.295"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"195.11","spread":"5.876"},{"groupId":"OG001","value":"216.24","spread":"6.230"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-31.52","spread":"4.996"},{"groupId":"OG001","value":"-8.20","spread":"5.081"}]}]}]},{"type":"SECONDARY","title":"Change in FPG From Baseline to Week 18 (LOCF)","description":"Adjusted mean change from baseline in FPG achieved with saxagliptin added on to metformin versus metformin at Week 18 (Randomized Analysis Set). FPG is a continuous measure, the change from baseline for each participant is calculated as the Week 18 value minus the baseline value.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"162.54","spread":"4.146"},{"groupId":"OG001","value":"163.35","spread":"3.910"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"142.70","spread":"3.633"},{"groupId":"OG001","value":"156.32","spread":"3.948"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-20.03","spread":"3.146"},{"groupId":"OG001","value":"-6.85","spread":"3.090"}]}]}]},{"type":"SECONDARY","title":"Percent of Subjects Reaching Goal (HbA1c <7%) at Week 18 (LOCF) - Percent of Subjects (1)","description":"Percent of subjects achieving therapeutic response (HbA1c \\<7.0%) at Week 18 (LOCF) (Randomized analysis set)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"37.2","spread":null},{"groupId":"OG001","value":"26.1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":138},"commonTop":["Nasopharyngitis","Diarrhoea","Urinary Tract Infection"]}}}